 |
Research |
Our growing pipeline includes novel investigational medications for the potential treatment of HIV, hepatitis B and C, respiratory and cardiopulmonary diseases. |
At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development programs currently focus on small molecule therapeutics for the potential treatment of HIV, hepatitis B and C and cardiovascular diseases. The company also has an active research program in inhaled therapeutics for the treatment of cystic fibrosis-related lung infections. Click here, to learn more about our ongoing research programs. Tenofovir disoproxil fumarate
Potential indication: Hepatitis B Awaiting FDA Action
Aztreonam Lysine for inhalation
Potential indication: Cystic Fibrosis Awaiting FDA Action
Darusentan
Potential indication: Resistant Hypertension Phase III
Elvitegravir (GS 9137)
Potential indication: HIV/AIDS Phase II
GS 9450 (LB84451; caspase inhibitor)
Potential indication: Hepatitis C/Fibrosis Phase II
GS 9131 (nucleotide prodrug)
Potential indication: HIV/AIDS Phase I
GS 9190 (polymerase inhibitor)
Potential indication: Hepatitis C Phase I
GS 9191 (nucleotide prodrug)
Potential indication: HPV Phase I
GS 9310/11 (inhaled fosfomycin/tobramycin)
Potential indication: Bronchiectasis/Cystic Fibrosis Phase I
GS 9219 (nucleotide prodrug)
Potential indication: Hematologic Cancers Phase I
Small Molecule Therapeutics
Potential indication: Viral Infections Preclinical
Small Molecule Therapeutics
Potential indication: Cardiovascular Preclinical
Inhaled Therapeutics
Potential indication: Respiratory Infections Preclinical
|